Revista de la Sociedad Peruana de Medicina Interna.       Vol. 15 • Nº 2 • 2002

 

REFERENCIAS BIBLIOGRÁFICAS

 

1. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris 3:94,1865.

2. Kakkar AK,Williamson RC. Prevention of thromboembolism in cancer using low molecular-weight heparins. Haernostasis 1997; 27 Suppl 1:32-7

3. Kakkar, et al. Extrinsic pathway activation in cancer with high factorVIla and tissue factor. Lancet 1995 Oct 14; 346 (8981): 1004-5

4. International multicentre trial. Prevention of fatal postoperative pulmonary embclism by low doses of heparin. Lancet 1975 Jul 12; 2 (7924):45-51

5. Levine MN, et al. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.Thromb Haemost 1997 Jul; 78 (1): 133-6

6. Prandoni P Lensing AW, Cogo A, Cuppini S,Villalta S, Carta M, Cattelan AM, Polistena R Bernardi E, Prins MH.The long-term clinical course of acute deep venous thrombosis.Ann Intern Med 1996 Jul 1; 125 (1): 1-7

7. Kakkar VV, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery.TheThromiphylaxis Collaborative Group. Lancet 1993 Jan 30; 341 (8840):259-65

8. Begovist Det al. Low molecular weight heparin started before surgery a prophylaxis against deep vein thrombosis:2500 versus 5000 Xal units in 2070 patients. BrJ Surg 1995; 82(4): 496-501

9. Monreal Malastrue A, Rull M,Mira X, Muxartj, Rosell Rabad A.Upper extremity deepvenous thrombosis in cancer patients with venous access devices prophylaxis with a low molecular weight heparin (Fragmin).Thromb Haemost 1996 Feb; 75 (2):251-3

10. Edmondson RA,Melissari F Kakkar. Low-molecular weight heparin versus warfarin for prevention of recurrentvenous thromboembolism:a randomized trial. World J Surg 1996 Jun; 20 (5):521-6; discussion 526-7

11. Green D, Hull RDBrant R, Pineo GE Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339 (8807):

12. Consenso Peruano sobre la trombosis venosa profunda y embolia pulmonar. Boletin Extraordinario de la Sociedad Peruana de Hematología. Lima, abri1 1999

13. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992; 18 (4): 353-372

14. Golberg Rj, Seneff M, GorejM, Andersen FA. Occult malignant neoplasm inpatient with deep venous thrombosis.Arch Inter Med 1987: 147: 251-25

15. Zurborn KH, Duschatt Gramj, Bruhn HD. Investigations of coagulation system and fibrinolysis in patients with disseminated adenocarcinomas and non Hodgkin Lymphomas. Oncology 1990; 47 (5):376-80

16. Monreal M, Fernandez-Llamazares j, Perandreu j, Urrutia A, Sahuquillo) C, Conte I E.Occultcancer in patients with venous thromboembolism:which patients, which cancers. Thromb Haemost 1997 Nov; 78 (5): 1316-8

17. Prandoni P, LensingAW, Buller HR, CogoA, Prins MH, Cattelan AM, et al. Deepvein thrombosis and the incidence of subsequent symptomatic cancer. N Englj Med 1992 Oct 15; 327 (16): 1128-33.

18. Nordstrom M, Lindblad B Anderson H,Bergqvist D, KjellstromT Deep thrombosis and occult malignancy an epidemiological study. BMJ 1994; 308 (6933): 891-4

19. Rossendal FR. Risk factors for venous thrombotic disease. Thrombosis and hemostasis 1989; 82: 6.

 

Atrás